A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study
Latest Information Update: 28 Jul 2022
Price :
$35 *
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ADVANCE
- 25 Jul 2022 Primary endpoint (Comparison of Sustained Viral Response at 12 Weeks Post Treatment (SVR12) in the Three Treatment Groups.) has not been met, according to Results published in the Journal of Viral Hepatitis.
- 25 Jul 2022 Results (n=110) assessing published in the Journal of Viral Hepatitis.
- 25 Oct 2021 The Primary end-point has been changed.